Similar articles for PMID: 27687309

Year	Number of Results
2009	1
2010	6
2011	2
2012	6
2013	10
2014	11
2015	23
2016	18
2017	15
2018	14
2019	11
2020	13
2021	20
2022	25
2023	6
2024	0

1

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.

An E, Ock CY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Liao WL, Cecchi F, Blackler A, Thyparambil S, Kim WH, Burrows J, Hembrough T, Catenacci DVT, Oh DY, Bang YJ. An E, et al. Ann Oncol. 2017 Jan 1;28(1):110-115. doi: 10.1093/annonc/mdw442. Ann Oncol. 2017. PMID: 27687309 Free PMC article.

2

Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.

Kadowaki S, Masuishi T, Eto T, Narita Y, Taniguchi H, Ura T, Ando M, Tajika M, Niwa Y, Yatabe Y, Muro K. Kadowaki S, et al. Cancer Chemother Pharmacol. 2017 Oct;80(4):807-813. doi: 10.1007/s00280-017-3422-6. Epub 2017 Aug 18. Cancer Chemother Pharmacol. 2017. PMID: 28821938

3

The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer.

Lee JY, Hong M, Kim ST, Park SH, Kang WK, Kim KM, Lee J. Lee JY, et al. Sci Rep. 2015 Mar 19;5:9289. doi: 10.1038/srep09289. Sci Rep. 2015. PMID: 25786580 Free PMC article.

4

EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.

Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH, Martens U, Kang YK, Rha SY, Cats A, Tokunaga M, Lordick F. Wagner AD, et al. BMC Cancer. 2019 May 24;19(1):494. doi: 10.1186/s12885-019-5675-4. BMC Cancer. 2019. PMID: 31126258 Free PMC article. Clinical Trial.

5

Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, Leon A, Alsina M, Visa L, Rivera F, Galan MC, Del Valle E, Vilardell F, Iglesias M, Fernandez S, Landolfi S, Cuatrecasas M, Mayorga M, Jose Paulés M, Sanz-Moncasi P, Montagut C, Garralda E, Rojo F, Hidalgo M, Lopez-Rios F. Gomez-Martin C, et al. J Clin Oncol. 2013 Dec 10;31(35):4445-52. doi: 10.1200/JCO.2013.48.9070. Epub 2013 Oct 14. J Clin Oncol. 2013. PMID: 24127447

6

Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression.

Dai GH, Shi Y, Chen L, Lv YL, Zhong M. Dai GH, et al. Hepatogastroenterology. 2012 Nov-Dec;59(120):2439-44. doi: 10.5754/hge12166. Hepatogastroenterology. 2012. PMID: 22534547 Clinical Trial.

7

Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis.

Wang HB, Liao XF, Zhang J. Wang HB, et al. Medicine (Baltimore). 2017 Nov;96(44):e8437. doi: 10.1097/MD.0000000000008437. Medicine (Baltimore). 2017. PMID: 29095284 Free PMC article. Review.

8

Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma.

Wang YK, Chen Z, Yun T, Li CY, Jiang B, Lv XX, Chu GH, Wang SN, Yan H, Shi LF. Wang YK, et al. World J Gastroenterol. 2015 Apr 21;21(15):4680-7. doi: 10.3748/wjg.v21.i15.4680. World J Gastroenterol. 2015. PMID: 25914479 Free PMC article.

9

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.

Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Rüschoff J. Van Cutsem E, et al. Gastric Cancer. 2015 Jul;18(3):476-84. doi: 10.1007/s10120-014-0402-y. Epub 2014 Jul 20. Gastric Cancer. 2015. PMID: 25038874 Free PMC article. Clinical Trial.

10

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.

Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL. Perez EA, et al. JAMA Oncol. 2016 Jan;2(1):56-64. doi: 10.1001/jamaoncol.2015.3239. JAMA Oncol. 2016. PMID: 26469139 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

152 results

Results by year